Sirtex Medical Limited Stock Rating Reaffirmed by CIMB (SRX)
Other equities research analysts have also recently issued reports about the stock. Analysts at Morningstar reiterated a “hold” rating on shares of Sirtex Medical Limited in a research note on Sunday, April 27th.
Sirtex Medical Limited (ASX:SRX) traded up 7.26% on Friday, hitting A$18.920. The stock had a trading volume of 467,411 shares. Sirtex Medical Limited has a 52-week low of A$10.780 and a 52-week high of A$19.100. The stock has a 50-day moving average of A$16.99 and a 200-day moving average of A$15.20. The company has a market cap of A$1.062 billion and a P/E ratio of 46.54.
Sirtex Medical Limited is a biotechnology and medical device company. The Company is engaged in manufacturing and to distribute liver cancer treatments utilizing particle technology to approved markets in Asia-Pacific, Europe and the United States.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.